Dr. Sanjay Rajagopalan, MD

Dr. Rajagopalan practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Rajagopalan's NPI, 1871582577, was assigned on October 17, 2005. Dr. Rajagopalan holds Maryland license D77012.

Dr. Rajagopalan's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Rajagopalan's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Rajagopalan is also affiliated with University Hospitals Ahuja Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Rajagopalan to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rajagopalan practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Rajagopalan's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Rajagopalan's licenses on file in 2 states: Maryland and Ohio.

CMS data shows 120 Medicare services from Dr. Rajagopalan across 5 procedure codes in 2024, for 142 Medicare patients. Medicare paid $7,910 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 142 Medicare patients who saw Dr. Rajagopalan in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rajagopalan's median patient age at 69, with 43% women.

In 2024, Dr. Rajagopalan wrote 883 Medicare Part D claims for 60 patients. 51% of them were for generic drugs. CMS names the drug for 726 of them, across 24 drugs with 11 or more claims each, at $405,131 in total drug cost. In 2023, CMS named 447 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Rajagopalan for performance year 2024, reported as part of a group. Dr. Rajagopalan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 415 general payments to Dr. Rajagopalan from 22 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Novo Nordisk Inc paid the most, $455,471.